<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285088</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-001</org_study_id>
    <secondary_id>2014-003555-62</secondary_id>
    <nct_id>NCT02285088</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease</brief_title>
  <official_title>A Phase I Randomised, Placebo-controlled, Double-blind, Single and Multiple Ascending Dose Study of the Tolerability and Pharmacokinetics of GBT440 in Healthy Subjects and Patients With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and
      pharmacodynamic effects of GBT440 compared with placebo in healthy subjects and subjects with
      sickle cell disease (SCD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, as assessed by frequency and severity of adverse events (AEs), and changes in vital signs, 12-lead electrocardiograms (ECGs), and laboratory assessments as compared to baseline</measure>
    <time_frame>30 - 118 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood and plasma area under the concentration time curve (AUC) of GBT440</measure>
    <time_frame>30 - 118 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood and plasma maximum concentration (Cmax) of GBT440</measure>
    <time_frame>30 - 118 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood and plasma time to maximum concentration (Tmax) of GBT440</measure>
    <time_frame>30 - 118 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of hemoglobin occupied or modified by GBT440</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in heart rate and pulse oximetry following exercise testing in healthy volunteers</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of sickled cells under ex vivo conditions</measure>
    <time_frame>30 - 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effect of GBT440 on hemolysis as measured by LDH, direct bilirubin, hemoglobin, and reticulocyte count</measure>
    <time_frame>30 - 118 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in pain as measured by visual analog scale</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in fatigue as measured by questionnaire</measure>
    <time_frame>30 - 118 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exercise capacity as measured by 6-minute walk test</measure>
    <time_frame>30 - 90 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>GBT440</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GBT440</intervention_name>
    <description>GBT440 will be administered as oral capsules</description>
    <arm_group_label>GBT440</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered as oral capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female of non-child bearing potential; 18 to 55 years old; are
             non-smokers and have not used nicotine products within 3 months prior to screening.

          -  Male or female, 18 to 60 years old, with sickle cell disease (hemoglobin SS,
             HbS/β0thalassemia, HbS/β+thalassemia, or HbSC) not requiring chronic blood transfusion
             therapy; without hospitalization in 30 days before screening or receiving blood
             transfusion within 30 days before screening; subjects are allowed concomitant use of
             hydroxyurea if the dose has been stable for the 3 months prior to screening.

        Exclusion Criteria:

          -  Subjects who have a clinically relevant history or presence of respiratory,
             gastrointestinal, renal, hepatic, haematological, lymphatic, neurological,
             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,
             dermatological, connective tissue diseases or disorders.

          -  Subjects who consume more than 14 (female subjects) or 21 (male subjects) units of
             alcohol a week.

          -  Subjects who have used any investigational product in any clinical trial within 30
             days of screening

          -  Subjects with sickle cell disease who smoke &gt;10 cigarettes per day; have hemoglobin
             level &lt;6 g/dL or &gt;10.4 g/dL (&gt; ULN (appropriately corrected for gender) for Cohort 15)
             at screening; have aspartate aminotransferase (AST) &gt;4x upper limit of normal or
             alanine aminotransferase (ALT), or alkaline phosphatase (ALK) &gt;3x upper limit of
             normal reference range (ULN) at screening; have moderate or severe renal dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josh Lehrer-Graiwer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Global Blood Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Mant, FRCP FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

